Cargando…

Patient Survival With and Without Radiation Therapy for Early-Stage Diffuse Large B-Cell Lymphoma in the Era of PET and Rituximab

PURPOSE: The benefit of radiation therapy (RT) becomes uncertain in the treatment of early stage diffuse large B-cell lymphoma (DLBCL) in the era of rituximab, positron emission topography (PET), and computed tomography (CT). We sought to retrospectively review modern patients with early stage I-II...

Descripción completa

Detalles Bibliográficos
Autores principales:	McLaughlin, Christopher, Ricco, Anthony, Singh, Raj, Mukhopadhyay, Nitai, Skoro, Nevena, Girma, Selamawit, Deng, Xiaoyan, Song, Shiyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Scientific Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260098/ https://www.ncbi.nlm.nih.gov/pubmed/35814857 http://dx.doi.org/10.1016/j.adro.2022.100930

Ejemplares similares

Eligibility Criteria Perpetuate Disparities in Enrollment and Participation of Black Patients in Pancreatic Cancer Clinical Trials
por: Riner, Andrea N., et al.
Publicado: (2022)

Primary breast diffuse large B-cell lymphoma in the era of rituximab
por: Zhang, Na, et al.
Publicado: (2016)

The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era
por: Kobayashi, T, et al.
Publicado: (2016)

Role of radiation therapy in primary breast diffuse large B‐cell lymphoma in the Rituximab era: a SEER database analysis
por: Liu, Pan‐pan, et al.
Publicado: (2018)

Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma Alliance
por: Boyle, Stephen, et al.
Publicado: (2021)

Importance of baseline PET/CT imaging on radiation field design and relapse rates in patients with Hodgkin lymphoma
por: Figura, Nick, et al.
Publicado: (2017)

Evaluation of the MD Anderson tumor score for diffuse large B‐cell lymphoma in the rituximab era
por: Gutierrez, Antonio, et al.
Publicado: (2020)

Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications
por: Papageorgiou, Sotirios G., et al.
Publicado: (2021)

The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance
por: Liu, Yizhen, et al.
Publicado: (2020)

Radiation Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma: What Is the Right Regimen for Palliation?
por: Wright, Christopher M., et al.
Publicado: (2022)

Primary breast diffuse large B‐cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure
por: Hu, Shaoxuan, et al.
Publicado: (2018)

Clinical outcome of Epstein–Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era
por: Sato, Ai, et al.
Publicado: (2014)

Relevance of prognostic index with β2-microglobulin for patients with diffuse large B-cell lymphoma in the rituximab era
por: Kang, Jihoon, et al.
Publicado: (2017)

An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era
por: Sun, Feifei, et al.
Publicado: (2018)

Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era
por: Seo, Seyoung, et al.
Publicado: (2016)

Modified Stage Grouping of Diffuse Large B-Cell Lymphoma Involving the Same Side of the Diaphragm in the Rituximab Era
por: Jeong, Hyehyun, et al.
Publicado: (2022)

Prognostic significance of interim PET/CT response for the treatment of advanced-stage marginal zone lymphoma in the post-rituximab era
por: Song, Ga-Young, et al.
Publicado: (2020)

Risk Factors of Progression in Low-tumor Burden Follicular Lymphoma Initially Managed by Watch and Wait in the Era of PET and Rituximab
por: Rodier, Cyrielle, et al.
Publicado: (2023)

Second Primary Malignancies in Diffuse Large B-cell Lymphoma Survivors with 40 Years of Follow Up: Influence of Chemotherapy and Radiation Therapy
por: Rock, Calvin B., et al.
Publicado: (2022)

Radiation Therapy in the German Hodgkin Study Group HD 16 and HD 17 Trials: Quality Assurance and Dosimetric Analysis for Hodgkin Lymphoma in the Modern Era
por: Oertel, Michael, et al.
Publicado: (2022)

Moderately Hypofractionated Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Prostate Cancer: Five-Year Toxicity Results From a Prospective Phase I/II Trial
por: Ricco, Anthony, et al.
Publicado: (2020)

Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab
por: Muylle, Kristoff, et al.
Publicado: (2015)

IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era
por: Chen, Xiangli, et al.
Publicado: (2020)

Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions
por: Pinnix, Chelsea C., et al.
Publicado: (2017)

Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era
por: de Oliveira Costa, Renata, et al.
Publicado: (2016)

Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era
por: Abi Jaoude, Joseph, et al.
Publicado: (2021)

A prognostic model, including the EBV status of tumor cells, for primary gastric diffuse large B‐cell lymphoma in the rituximab era
por: Ishikawa, Eri, et al.
Publicado: (2018)

Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma
por: Yelvington, Bradley J.
Publicado: (2018)

Effectiveness of low-dose radiation for primary cutaneous anaplastic large cell lymphoma
por: Smith, Grace L., et al.
Publicado: (2017)

Pilot/Phase II Trial of Hypofractionated Radiation Therapy to the Whole Breast Alone Before Breast Conserving Surgery
por: Thorpe, Cameron S., et al.
Publicado: (2022)

Impact of the double expression of MYC and BCL2 on outcomes of localized primary gastric diffuse large B-cell lymphoma patients in the rituximab era
por: Kawajiri, A, et al.
Publicado: (2016)

Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: a retrospective analysis
por: Fan, Liping, et al.
Publicado: (2021)

Prognostic Impact of Age at the Time of Diagnosis in Korean Patients with Diffuse Large B-cell Lymphoma in the Rituximab Era: A Single Institution Study
por: Hwang, Hee Sang, et al.
Publicado: (2021)

Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era
por: Yuda, Sayako, et al.
Publicado: (2016)

A Clinico-Genotypic Prognostic Index for De Novo Composite Diffuse Large B-Cell Lymphoma Arising from Follicular Lymphoma in Asian patients treated in the Rituximab Era
por: Lim, Ryan Mao Heng, et al.
Publicado: (2020)

Role of Radiation Therapy Differs Between Stages in Primary Bone Large B-Cell Lymphoma in Rituximab Era: A Population-Based Analysis
por: Ma, Shengling, et al.
Publicado: (2020)

P1200: RELAPSE AND OCCURRENCE OF SECOND PRIMARY MALIGNANCIES IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA IN RITUXIMAB ERA, A NATIONWIDE OBSERVATIONAL STUDY
por: Lee, H. J., et al.
Publicado: (2022)

Proton Radiation Therapy After Chemotherapy in the Management of Aggressive Mediastinal Non-Hodgkin Lymphomas: A Particle Therapy Cooperative Group Lymphoma Subcommittee Collaboration
por: Baron, Jonathan A., et al.
Publicado: (2022)

18F-FDG PET response and clinical outcomes after stereotactic body radiation therapy for metastatic melanoma
por: Youland, Ryan S., et al.
Publicado: (2017)

Predictors of central nervous system involvement in diffuse large B-cell lymphoma: a divining rod is wanted
por: Ferreri, Andrés José María
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5l34avn065ahe4kn7ncsisk5v6